Articles reporting the diagnostic accuracy of non-invasive prenatal diagnostic (NIPD) tests for RHD genotyping using fetal material extracted from maternal blood have been published steadily for over a decade. Health care providers in Europe have started to use this technology for management of the small number of sensitised pregnancies (ca. 220-600 per annum in the Netherlands, Germany, France and the UK). Scientists and clinicians are also advocating widespread implementation for the far larger number of non-sensitised RhD-negative pregnancies (ca. 34,000-125,000 per annum in the same countries). Largescale, prospective trials are only now underway. Estimates of the technical performance of these tests are currently based on results from small-scale studies, together with formal meta-analysis. The issue of early assessment of test performance is one faced by many new genetic tests. As part of a wider study we have investigated the quality of reporting of diagnostic accuracy in publications and produced guidelines for future studies.
Introduction
Fetal RHD genotyping from maternal whole blood [1] , fetal cells [2] or cell free fetal DNA [3] in maternal blood has been feasible for over a decade. Following the first papers, research interest in this form of non-invasive prenatal diagnosis (NIPD) has become global. Publications in Europe, America and Australia aim to improve the management of pregnancies of women who are rhesus negative [2, [4] [5] [6] [7] [8] [9] . In white Caucasian populations about 10% of all pregnancies involve an RhD-negative mother and an RhD-positive fetus, potentially placing the mother at risk of sensitisation and future babies at risk of haemolytic disease of the fetus and newborn (HDFN).
Anti-D immunoglobulin can be given to prevent a woman producing antibodies against fetal RhD-positive blood cells. Introduction of postnatal anti-D prophylaxis (within 72 h of delivery) in the late 1960s reduced sensitisation and HDFN rates considerably internationally. Combined with antenatal prophylaxis for high-risk events, such as amniocentesis, this form of targeted prophylaxis has proved highly effective and cost-effective [10] . Consequently, the number of sensitised RhD-negative women who give birth every year is lower than 1% of total births.
For non-sensitised women, routine antenatal anti-D prophylaxis (RAADP) at 28-30 weeks gestation was introduced in the mid1990s, and is now available in most European countries. However, 40% of RhD-negative women receive this blood product unnecessarily because the fetus is not RhD-positive. Fetal RHD genotyping has the potential to enable targeted antenatal prophylaxis only for women whose pregnancy is at risk. This might address any issues of limited anti-D supplies and perceived risk associated with unnecessary administration of a blood product.
The NIPD RHD genotyping test has already started to have an impact on the management of sensitised women, in countries where this technology is available, by replacing invasive procedures like amniocentesis for the determination of fetal RhD status. Replacement of amniocentesis is desirable since the procedure can promote feto-maternal blood exchange as well as being associated with a small increased risk of miscarriage [11, 12] .
The current state of development of the RhD NIPD test is promising. Several studies have reported high accuracy rates [13] [14] [15] [16] and these have prompted the initiation of larger scale trials in the Netherlands, Germany and the UK [17] [18] . Reports in the literature have already led to initial use of the test for management of sensitised women. An increasing focus of debate is now on widespread implementation of the test in non-sensitised pregnancies [19] . Discussion of markers (exons and/or introns) to be used for RHD genotyping, and the applicability of NIPD tests for routine clinical use in diverse populations form part of this debate [13, 17] .
A recent meta-analysis undertaken by Geifman-Holtzman et al. has reported sensitivity and specificity values of 0.986 and 0.954 respectively, and an overall positive predictive value of 0.990 and negative predictive value of 0.921 [20] . Some studies were excluded from this meta-analysis on the basis of sample numbers, but aspects such as study quality were not considered. Because assessment of the quality of reporting of diagnostic accuracy can be problematic, a world-wide Delphi panel has identified agreed international quality criteria for assessing the reporting of such studies [21] . The resulting checklist (STARD -standards for reporting studies of diagnostic accuracy) is now required from all authors of health technology assessment reports of diagnostic technologies in the UK, and increasingly requested by editors of international journals. We have undertaken an independent systematic literature search and assessed the quality of reporting of all identified articles using the STARD checklist. We further investigated the implications of any shortcomings on the generalisability of NIPD study results, in order to identify key aspects influencing test reliability and any underlying reporting biases. An NIPD assessment proforma has been produced as well as recommendations that are specific and relevant for reporting diagnostic accuracy of RhD NIPD tests.
Methods

Literature search strategy
Published articles were identified by systematic searches of electronic databases from 1966 until January 2007; these included PubMed, Ovid Medline, Ovid Embase, the Cochrane Library, the National Library for Health (UK), Online Computer Library Center (OCLC) and the Conference Papers Index. Text words and MeSH headings used separately and in combination included: prenatal diagnosis, Rh, fetal cells, fetal DNA, maternal blood, serum, plasma, Rh alloimmunis(z)ation. Bibliographies of all papers identified were examined. Searches for related articles by topic and author were carried out in PubMed where possible. No restriction was set on publication type or language.
Selection process for papers for review
All retrieved publications were read and assessed in respect of study type, patient/sample numbers and the stated study aim/ research question. Papers not in English were translated. Studies that contained information on the diagnostic accuracy of RhD NIPD were identified. Short abstracts, letters and case reports were excluded due to limited data content. Similarly, small studies with fewer than 10 samples were excluded. Phrases used to identify studies as diagnostic accuracy papers included: accuracy/detection rate; sensitivity and specificity; evaluation of test reliability; efficiency and feasibility.
Data extraction and quality assessment
A spreadsheet was prepared to extract information from the articles finally selected. This included: year and country of publication; number of patients/samples; source and type of fetal material; number of replicates and exons tested; number of positive replicates required for a result to be categorised as positive; test failure/inconclusive result rates; accuracy measures reported.
Papers were then scored against the STARD checklist of 25 items, resulting in a score out of 25 for each paper which corresponded to the paper's quality as a study reporting diagnostic accuracy. Coverage of the 25 STARD items by the 27 studies was also reported (Table 1 ).
An in-house proforma was developed by collating the eight main points of the data extraction form and categorising these under the key elements of design deficiencies [22] . Papers were also assessed against this.
Results
The literature search resulted in the identification of 51 publications. The selection procedure described above excluded 24 papers (Fig. 1 ) leaving 27 studies for final quality assessment ( Table 2 ). Of these, 25 were in English, 1 in French and 1 in Polish. Publication dates ranged from 1996 to the end of 2006. Findings were published in a wide range of journals and originated from 15 countries. a Coverage is a measure of how well the studies have adhered to items of STARD checklist (coverage = P (scores)/total papers), where studies covering checklist item well score 1 point, partially 1/2 point and no coverage 0 points).
b Phrases used to identify studies as diagnostic papers included: accuracy/detection rate, sensitivity and specificity, evaluation of test reliability, efficiency and feasibility. c Studies scored as long as they mentioned: evaluation or determination of test accuracy, evaluation of test reliability, efficiency and feasibility of test.
Assessment against the STARD checklist
All studies were assigned a low score based on the STARD checklist. Scores ranged from as low as 5/25 to 13/25 points. Studies demonstrated weaknesses in particular elements of the STARD checklist, as shown in Table 1 . Quality of reporting was not related to publication date or country of study. The great majority of authors identified their paper as a report on diagnostic accuracy (STARD item No. 1) and nearly all authors stated their aim to be assessment of the feasibility of RhD NIPD tests (No. 2). However, fewer than one in three actually used the recommended MeSH heading 'sensitivity and specificity' required for indexing papers on diagnostic accuracy.
When reporting study methods, articles generally lacked information on the population providing the samples, including how participants were recruited and which women were selected, and whether data was collected prospectively or retrospectively (Nos. [3] [4] [5] [6] . All these will affect the comparability as well as quality of study findings. Linked to this, the degree of blinding of test readers (No. 11) and the statistical methods used to quantify uncertainty (No. 12) were also rarely reported in studies, while test reproducibility (No. 13) was not covered at all. On the other hand, materials and methods (No. 8) were well described. The reference standard (No. 7) was mentioned in all but two studies but rarely described comprehensively. Numbers and training of test readers (No. 10) were rarely reported, and cut-off or category of result (No. 9) was not covered in any of the studies.
When reporting results, the actual date of the study was rarely recorded (No. 14). Details of the study population generally only included information on the gestational age of the fetus but not the characteristics of women (No. 15). The proportion of participants satisfying criteria for inclusion was also rarely reported (No. 16 A detailed comparison of STARD checklist scores across papers would appear to indicate that articles have consistent weaknesses in their reporting, and published studies may, therefore, not be free from bias, with some indication that reported diagnostic accuracy rates may be overestimates. In terms of their applicability to the service setting, certain STARD items could have major implications for clinical implementation of NIPD testing for fetal RHD genotyping, while others might not apply directly to the NIPD test being evaluated. For instance, a description of cut-offs and categories (STARD list item No. 9) is not obviously applicable to RhD NIPD. Any differential implication that specific items might have for clinical application of RhD NIPD is not reflected in the final score since all STARD items carry equal weight. The STARD score, therefore, should not be interpreted as a stand-alone measure of the quality of studies of RhD NIPD diagnostic accuracy. There may be specific questions and unique characterisations which are important for this type of genetic diagnostic tool.
Assessment against NIPD proforma
An in-house proforma translated the list of general shortcomings identified by STARD into areas of weakness specifically relevant to RhD NIPD accuracy. Four main areas, previously reported by the STARD group [22] , incorporating eight specific aspects, were identified as most likely to compromise the internal as well as external validity of NIPD studies (Table 2) . A lack of discussion of flaws in these areas might lead to inappropriate decisions on adoption of the test. Table 2 clearly indicates that a number of researchers concentrated on samples from at risk pregnancies (e.g. Down syndrome), including women who may not resemble the general RhD-negative pregnant population [5, 8, 9, 15, [23] [24] [25] [26] . Since recruitment was carried out selectively, test accuracy reported in such studies might be an overestimate because certain fetal conditions 
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such as Down syndrome can lead to higher levels of fetal DNA in the maternal circulation [27] , consequently increasing the sensitivity of the test. Only 5 studies made reference to the sensitisation status of the sample population [6, 15, 16, 28, 29] . Poor characterisation of the sample population or selective sampling might affect the reliability of reported results equally. Selective sampling was taken even further in two studies that only recruited RhD-negative pregnant women with RhD-positive fetuses [15, 29] . Both studies excluded any possibility of producing false positives and did not sufficiently challenge the test because a certain test outcome was anticipated. This is also true for one study that included samples from four women with weak D phenotypes [30] . Fetuses of women with such a phenotype cannot currently be tested non-invasively. While identification of such individuals is an important feature of the test in order to avoid false positives, knowledge of inclusion of such samples, again, implies an anticipation of identifying these four women. Restriction of samples to Caucasians also reduced the validity of findings, as did failure to report the ethnic make-up of the study population (20 studies). This is particularly relevant for RHD genotyping because of the genetic variation observed in different ethnic groups. Only four studies specifically identified their study populations as of mixed ethnicity [13, 25, 31, 32] .
Study conduct and data analysis
A third aspect concerns the handling of data on replicate samples. Twenty studies reported the number of replicates used, which ranged from two to seven for fetal DNA samples and up to 11 when using fetal cells. Out of these, five studies used a different number of replicates for different samples [9, 14, 30, 33, 34] and four studies presented no, or insufficient, information on how replicates were handled. Seven studies either did not include replicates or did not report them. Protocols for conversion of replicate outcomes into an overall test result differed significantly across the studies, ranging from a requirement for one or more positive replicate outcome [2, 13, 28, 29, 30, [32] [33] [34] to two or more [6, 16, 25, 35] or all replicates [14, 15, 31, 35, 36] to be positive for an overall positive result.
A fourth aspect relates to reporting of test failure rates and whether the reported accuracy is adjusted for the number of retests. A test failure rate, which is derived from the number of excluded samples due to inconclusive results, lack of material or maternal variant genes, was reported in only 12 studies [4] [5] [6] [13] [14] [15] [16] 25, [29] [30] [31] 35] . Out of these, only one group of authors considered the failure rate in their analysis of test accuracy [31] and one mentioned the revised overall success rate only in their comments [15] . In all studies that provided data on their test failure rate, inclusion of these samples would result in a lower accuracy [13] [14] [15] [16] 25, [29] [30] [31] 35] . This was also demonstrated in a recent meta-analysis [20] .
Study design
A final two aspects concern the controls included in a study. Ideally, for RhD NIPD these should include (a) controls of known RhD genotypes and (b) controls for the presence of fetal material. Use of control samples of known RhD type (positive as well as negative) and run at the same time as the index test was reported in only 10 studies [4, 5, 13, 15, 25, 29, 32, [37] [38] [39] . Only two of these were controls from pregnant women with known RhD-positive ornegative fetuses. The other studies used control samples from males, non-pregnant females or combinations of both. Controls of known RhD variants that some studies claimed to be able to distinguish were not reported in those papers.
Use of a control for the presence of fetal DNA was reported in only seven studies [9, 13, 14, 16, 31, 32, 36] . There was no consistency in the type of control used. Y-linked markers were used in two studies but these are unable to provide a positive control for female fetuses [9, 34] . Insertion deletion polymorphisms (IDPs) were used in four studies; these are sex independent and appear reasonably robust [14, 16, 31, 36] . However, using 11 [14] and 8 [31] IDPs, the authors report that the presence of fetal DNA could not be confirmed in a small number of samples. Spiking samples with mouse DNA was not sufficient as a control for the presence of DNA [5] , since a true control requires DNA of fetal origin. Employment of RHCE as a control for fetal DNA in a further study was not sufficient because of the maternal genetic background [13] .
Discussion
Articles which report the diagnostic accuracy of new noninvasive prenatal diagnostic tests for RHD genotyping are difficult to identify through systematic searches of the literature. Indexing of the articles identified was found to be poor, as has been reported by other diagnostic test reviews [40] . Of those finally identified, less than one-third were found to have included the correct MeSH headings for diagnostic accuracy.
A detailed appraisal of all retrieved articles has identified a generally poor quality of reporting when papers are scored against international standards for studies reporting diagnostic accuracy and against an in-house NIPD proforma. The weaknesses identified are similar to those mentioned in two recent papers [41, 42] . The shortcomings observed will be significant if they cause the final test accuracy, after adjustment, to fall below a level that is acceptable in the context of their proposed clinical use [41] .
A recent publication reviewing the current stage of RhD NIPD test development reported a test diagnostic accuracy of >99% [43] . At the same time, a meta-analysis of published studies has reported an accuracy of 94.8% [20] . While an accuracy of >99% might be sufficiently high for a diagnostic test in clinical practice, an accuracy rate of 94% has been identified as suboptimal for clinical practice [41] . Further in their meta-analysis GeifmanHoltzman et al. [20] report an overall accuracy rate of only 91.4% when considering all samples, including those that had been excluded by study authors. Our review indicates widespread exclusion of inconclusive results, and of samples with insufficient fetal material or those with maternal variant genes, which will both have important implications for population wide implementation. This is apparent when one considers that in clinical practice all such samples excluded from an analysis would represent individuals for whom the test cannot produce a result. Although the two main factors that will limit broad-scale application of RhD NIPD are false negatives and false positives, it is, therefore, important to also achieve a reduction in the number of excluded samples.
False negatives may be due to lack of fetal material as well as suboptimal test sensitivity. However, an internal control to routinely confirm the presence of fetal DNA in the sample is not yet available [13] . Sex independent controls such as IDPs cannot be used as internal controls and highly polymorphic short tandem repeats (STRs), although discussed as a potential control, are reported to exhibit much lower sensitivity than the sensitivity for RHD genotyping [25] . Lack of a suitable control is currently a major limitation of the test for clinical practice.
Our review also identified particular study weaknesses in patient sampling. Selective participant sampling can result in a study population that does not resemble the general population to be tested in clinical practice. Similarly, a lack of consistency in the handling and reporting of replicates will limit the generalisability of study findings. Randen et al. [34] reported a decrease in the number of false results and an increase in accuracy when only one positive result, rather than all replicate outcomes, were considered. Reported test performance is, therefore, laboratory specific and might not be replicated in routine clinical practice.
All the articles identified in this review are based on data from a single laboratory, with tests undertaken under varying protocols, and results mostly derived from small sample numbers. The establishment of large-scale, standardised RhD NIPD test protocols is a key objective of the Special Non-invasive Advances in Fetal and Neonatal Evaluation (SAFE) Network established by the European Commission (www.safenoe.org).
To date, a major weakness in terms of the emerging evidence base of RhD NIPD has been the lack of any objective discussion regarding these various flaws and their consequences for implementation in clinical practice. Furthermore, due to the lack of peer-reviewed studies reporting on high-throughput testing of non-sensitised women, discussion of the implementation of this test application is based on results from small-scale studies. Since it implies testing a much larger number of women, the evidence base from small-scale studies should not be taken forward to largescale testing of non-sensitised women. For instance, the number of retests will determine the cost of the test, as well as its reliability. No articles address the issue of cost versus quality. Although our review has concentrated on the quality of studies in terms of their reporting of diagnostic accuracy, and not on scientific aspects such as the primers employed, the latter are also important. Scientific aspects will inevitably affect the ultimate accuracy of the test in the wider population since they determine which of the many variants would be detected or missed.
In conclusion, based on our findings we would recommend that following standardisation to identify best practice for methodology and materials for RhD NIPD, consensus should also be reached on the required number and handling of replicates, since test accuracy was observed to be repeatedly improved in papers by discounting dissimilar replicates [14, 30, 33] or sample test outcomes [2, 6, 14, 30, 35, 37] .
Furthermore, when carrying out meta-analyses, methods to take account of the quality of studies as well as their sample size should be considered since disregard of the quality of NIPD study design may lead to erroneous conclusions about test accuracy. High-quality trials evaluating the diagnostic accuracy of RhD NIPD tests are urgently needed. Examination of articles published to February 2008 identifies a continued absence of large-scale, peer-reviewed trials. We would recommend that such studies adhere to the STARD checklist and the recommendations (Fig. 2 ) specific for NIPD, and that these are consulted at the planning stage of all future NIPD studies.
